TORONTO, June 12, 2012 /CNW/ - Spectral Diagnostics Inc., (TSX:SDI, OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for
patients with septic shock, today announced that Dr. Paul Walker, the
Company's President and Chief Executive Officer, will present at the
Bloom Burton & Co. Healthcare Investor Conference on Thursday, June 21,
at 10:00 am Eastern Time. The conference will be held at the Toronto
Board of Trade in Toronto, Ontario.
Dr. Walker will provide a corporate update, including information about
the Company's pivotal sepsis program.
The Bloom Burton & Co. Healthcare Investor Conference brings together
U.S., Canadian and European investors who are interested in the latest
developments in the Canadian healthcare sector. Attendees will have an
opportunity to obtain corporate updates from the premier Canadian
public and private companies through presentations and break-out Q&A
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead
theranostics product for the treatment for severe sepsis and septic
shock. Toraymyxin is a therapeutic hemoperfusion device that removes
endotoxin, which can cause sepsis, from the bloodstream. Directed by
the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared
diagnostic for the risk of developing sepsis. Spectral's EUPHRATES
trial is the world's first theranostics trial in the area of sepsis.
Toraymyxin has been approved for therapeutic use in Japan and Europe,
and has been used safely and effectively in more than 80,000 patients
to date. In March 2009, Spectral obtained the exclusive development and
commercial rights in the U.S. for Toraymyxin, and in November 2010,
signed an exclusive distribution agreement for this product in Canada.
More than 250,000 patients are diagnosed with severe sepsis and septic
shock in North America each year, representing a greater than $1
billion market opportunity for Spectral. Spectral is listed on the
Toronto Stock Exchange under the symbol SDI, and on the OTQ QX under
the symbol DIAGF. For more information please visit www.spectraldx.com
About Bloom Burton & Co.
Bloom Burton & Co. is Canada's largest and most active
healthcare-specialized investment banking group. The team of healthcare
specialists merges scientific, medical, clinical, intellectual property
and commercial expertise with a strong understanding of the capital
markets, to advise and raise capital for private and public companies.
For more information, please visit www.bloomburton.com.
SOURCE Spectral Diagnostics Inc.
For further information:
Executive Vice President and CFO
416-626-3233 ext. 2200
Media and Investor Relations
416-815-0700 ext. 225